DEF 14A: LeMaitre Vascular Seeks Stockholder Approval for Amended Stock Option Plan, Director Elections and Executive Compensation on the Agenda

Sentiment:

Proxy Statement 16 April 2024 12:01 PM

LeMaitre Vascular is soliciting proxies for its 2024 Annual Meeting of Stockholders, focusing on director elections, executive compensation, and approval of an amended stock option plan.

Summary

LeMaitre Vascular, Inc. is holding its 2024 Annual Meeting of Stockholders on June 3, 2024, to vote on several key proposals.
Stockholders will elect three Class III directors, provide an advisory vote on executive compensation, approve the Fourth Amended and Restated 2006 Stock Option and Incentive Plan, and ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm for 2024.
The Board of Directors recommends voting FOR all proposals.
The record date for determining stockholders eligible to vote is April 5, 2024.
As of April 5, 2024, there were 22,445,999 shares of common stock outstanding and entitled to vote.
The Fourth Amended and Restated 2006 Stock Option and Incentive Plan seeks to add 1,000,000 shares to the existing share reserve and eliminate liberal share recycling.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting financial growth and strategic initiatives. The inclusion of risk factors and governance policies provides a balanced perspective.

Positives

The Board of Directors is actively engaged in risk oversight, including financial, strategic, operational, cybersecurity, ESG, legal, and regulatory risks.
The company has a Compensation Recovery Policy (Clawback Policy) in place.
The Board has determined that five directors are independent: Lawrence J. Jasinski, John J. O'Connor, Bridget A. Ross, John A. Roush, and Martha Shadan.
Stockholders indicated their support of the executive compensation with more than 97% of the votes cast in favor of our executive compensation program at the 2023 Annual Meeting of Stockholders.

Risks

The document mentions areas of material risk to the Company, including financial, strategic, operational, cybersecurity, environmental, social and governance (ESG), legal and regulatory risks.
The company's Clawback Policy provides for the mandatory recovery of erroneously awarded incentive-based compensation from Covered Officers of the Company if the Company is required to prepare a financial restatement.

Future Outlook

The company aims to continue granting stock options and other equity awards to attract new employees and directors, retain existing employees, and incentivize them to increase stockholder value.

Management Comments

George W. LeMaitre, Chairman and Chief Executive Officer, invites stockholders to attend the 2024 Annual Meeting and encourages them to provide comments and feedback.
The Board believes that combining the positions of Chief Executive Officer and Chairman helps to ensure that the Board and management act with a common purpose and provides a single, clear chain of command to execute our strategic initiatives and business plans.

Industry Context

The document references the iShares US Medical Devices ETF Index (Ticker: IHI) as a peer group for TSR comparison, indicating the company's performance relative to the medical device industry.

Comparison to Industry Standards

The company compares its total shareholder return (TSR) to the iShares US Medical Devices ETF Index (Ticker: IHI).
The company's 4-year cumulative TSR is greater than the companies included in our industry index, the iShares US Medical Devices ETF Index (Ticker: IHI).

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Code of Business Conduct and Ethics	The company has adopted a Code of Business Conduct and Ethics that applies to all directors, officers, and employees.	N/A	Aims to maintain high standards of business conduct and corporate governance.
Corporate Governance Guidelines	The Board of Directors has adopted Corporate Governance Guidelines, which, in conjunction with our Charter, Amended and Restated By-Laws, Board committee charters, and key Board policies, form the framework for our governance.	N/A	Provides a framework for corporate governance.
Director Independence	The Board has affirmatively determined that the following five directors are independent directors within the meaning of the applicable Nasdaq listing standards: Lawrence J. Jasinski, John J. OConnor, Bridget A. Ross, John A. Roush and Martha Shadan.	N/A	Ensures compliance with Nasdaq listing standards.
Director Resignation Policy	The Board has adopted a Director Resignation Policy, which provides that any nominee for director in an uncontested election who does not receive a majority of the votes cast shall submit his or her offer of resignation for consideration by the Nominating and Corporate Governance Committee.	N/A	Provides a mechanism for addressing directors who do not receive majority support.

Stakeholder Impact

Shareholders are provided with information to make informed decisions regarding director elections, executive compensation, and the stock option plan.
Employees are impacted by the company's compensation policies and equity incentive plans.
The company's performance and governance practices can impact its relationships with customers, suppliers, and creditors.

Next Steps

Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
The Board of Directors and Compensation Committee will consider the results of the advisory vote on executive compensation in their periodic reviews.
The company will continue to monitor and assess areas of material risk.
The company will comply with the Clawback Policy.

Key Dates

Date	Description
2003	Lawrence J. Jasinski has served as a member of our Board of Directors since 2003.
2005	Trent G. Kamke has served as our Senior Vice President, Operations since 2005.
2006	Helen Goulding joined us in 2006
2007	Joseph P. Pellegrino, Jr. has served as our Chief Financial Officer since 2007
2008	John J. OConnor has served as a member of our Board of Directors since 2008.
2009	Giovannella Deiure joined us in 2009
2011	Ina Leininger joined us in 2011
2013	Christopher D. Minnett joined LeMaitre in 2013
2014	John A. Roush has served as a member of our Board of Directors since 2014.
2015	The number of shares available for issuance under the Current Plan has not been increased since 2015.
2016	Joseph P. Pellegrino, Jr. has served as a member of our Board of Directors since October 2016.
2018	Jacob Petersen joined us in 2018
April 2020	Bridget A. Ross has served as a member of our Board of Directors since April 2020.
October 2020	James Russell has served as our Vice President, Production and Supply Chain since October 2020.
September 2022	Martha Shadan has served as a member of our Board of Directors since September 2022.
January 2023	Ryan H. Connelly has served as our Senior Vice President, Advanced Manufacturing Engineering, since January 2023
April 2023	David Hissong has served as our Vice President, General Counsel since April 2023.
April 2023	Kathryn L. Tebbe has served as our Senior Director, Financial Reporting since April 2023.
December 2023	Daniel J. Mumford has served as our Senior Director, Human Resources since December 2023.
April 5, 2024	Record date for determining stockholders eligible to vote at the meeting.
April 8, 2024	Board approved the Fourth Amended and Restated 2006 Plan.
April 16, 2024	Date of the proxy statement.
June 3, 2024	Date of the Annual Meeting of Stockholders.
December 17, 2024	Deadline for stockholder proposals for inclusion in the 2025 proxy statement.
February 3, 2025	Earliest date for submitting stockholder proposals for the 2025 Annual Meeting (outside of proxy statement inclusion).
March 5, 2025	Latest date for submitting stockholder proposals for the 2025 Annual Meeting (outside of proxy statement inclusion).

Keywords

stockholders, directors, compensation, incentive plan, proxy statement, LeMaitre Vascular, annual meeting, voting, Grant Thornton

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.